KYMR Kymera Therapeutics, Inc.

NASDAQ
$138.86

Kymera Therapeutics, Inc. (KYMR) is expected to report earnings on January 28, 2027, before the market open. The consensus earnings estimate is a loss of $1.29 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.3% since its last earnings release on October 29, 2026.

Kymera Therapeutics Missed Consensus Estimates
Thursday, October 29, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Jan 28
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($1.29)
Rev est $6.51M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $128.87

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Kymera Therapeutics, Inc.

Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.